Changes

# Client is interested in finding out about To map the existence and status of pending patent applications and patents filed in Russia (either directly at the Russian patent office or via the Eurasian Patent Office) that are directed at anti-TNFalpha antibodies, including antibodies such as infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), and golimumab (Simponi), and their uses.  Additional information about the key players in Europa and Asia in this field appear to be:  * Centocor (Johnson & Johnson) in the US* Mitsubishi Tanabe Pharma in Japan* Xian Janssen in China* Schering-Plough for Remicade and Simponi* Abbott (formerly BASF Knoll) * Cambridge Antibody Technology (now part of Medimmune) for Humira; * UCB Pharma SA for Cimzia* Centocor (Johnson & Johnson)